A new genomic cancer research partnership between the Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute and the biotechnology company NovellusDx was recently announced.
The Gene Editing Institute has licensed its innovative gene editing technology to Jerusalem-based NovellusDx to improve the efficiency and speed of NovellusDx’s cancer diagnostic screening tools. With the use of advanced gene editing technology, NovellusDx will be able to identify the genetic mechanism responsible for the onset and progression of cancer and determine effective cancer therapy. NovellusDx will pay royalties to Christiana Care for ten years for the use of its innovative gene editing technology.
NovellusDx will use the gene editing tools to help determine which drug is best for individual patients by recreating the mutations in a test system and then screening a series of known cancer drugs against those mutations to determine their efficacy.
Using the licensed gene editing technology from the Gene Editing Institute, NovellusDx will be able to define the impact of each mutation on the activity of signaling pathways of the tumor and suggest the most effective therapy to the patient’s physician.
A $900,000 grant from the U.S.-Israel Binational Industrial Research and Development Foundation in December 2016 facilitated the Gene Editing Institute-NovellusDx partnership. The BIRD Foundation promotes collaboration between U.S. and Israeli companies in a wide range of technological fields for the purpose of joint product development.